• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, March 30, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

Placebo and valium are equally effective for acute lower back pain in…

Bioengineer.org by Bioengineer.org
January 24, 2018
in Headlines, Health, Science News
Reading Time: 2 mins read
2
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: American College of Emergency Physicians

WASHINGTON — Emergency patients treated with naproxen and placebo had outcomes as good as or better than patients treated with naproxen and diazepam (trade name Valium) for acute lower back pain, according to the results of a double-blind, randomized clinical trial published last week in Annals of Emergency Medicine ("Diazepam Is No Better Than Placebo When Added to Naproxen for Acute Low Back Pain").

"Our study contributes to the growing body of literature indicating that, in general, most medications do not improve acute lower back pain," said lead study author Benjamin Friedman, MD, MS, of the Albert Einstein College of Medicine/Montefiore Health System in Bronx, New York. "One week after being discharged from the emergency department, lower back pain patients had improved equally, regardless of whether they were treated with naproxen and diazepam or naproxen and placebo. By three months after visiting the emergency department, most patients had recovered completely, regardless of what treatment they received."

Researchers randomized 114 patients who came to the emergency department with new-onset lower back pain to two groups: one group was treated with a combination of naproxen (a non-prescription, non-steroidal anti-inflammatory medication) and diazepam and the other was treated with a combination of naproxen and placebo. One week after visiting the emergency department, the diazepam group improved by 11 points on the Roland Morris Disability Questionnaire, as did the placebo group.

After one week, 31.5 percent of the diazepam patients reported moderate or severe lower back pain, while 21.8 percent of the placebo patients did. At three months, 12 percent of diazepam patients reported moderate or severe lower back pain, while 9 percent of placebo patients did. The differences are not considered clinically or statistically significant.

"Millions of patients come to the ER every year seeking relief for back pain, which can be debilitating," said Dr. Friedman. "Unfortunately, we have yet to come up with the silver bullet in pill form that helps them. If anything, we may be overmedicating these patients."

###

Annals of Emergency Medicine is the peer-reviewed scientific journal for the American College of Emergency Physicians, the national medical society representing emergency medicine. ACEP is committed to advancing emergency care through continuing education, research, and public education. Headquartered in Dallas, Texas, ACEP has 53 chapters representing each state, as well as Puerto Rico and the District of Columbia. A Government Services Chapter represents emergency physicians employed by military branches and other government agencies. For more information, visit http://www.acep.org.

Media Contact

Julie Lloyd
[email protected]
202-370-9292
@emergencydocs

http://www.acep.org

Share12Tweet7Share2ShareShareShare1

Related Posts

Breakthrough Discovery: Novel Biomarker Identified for Immunoglobulin A Nephropathy

March 30, 2026

Unraveling the Role of DNASE1L2 Intron Retention in Tuberculosis Progression

March 30, 2026

New National Digital Series Highlights Evidence-Based Lifestyle Strategies to Achieve Type 2 Diabetes Remission

March 30, 2026

HEAPGrasp: Enhancing Robot Dexterity with Just an RGB Camera for Faster, Smarter Object Handling

March 30, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1005 shares
    Share 397 Tweet 248
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Advancements in EV Battery Technology to Surpass Climate Change-Induced Degradation

    45 shares
    Share 18 Tweet 11

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Breakthrough Discovery: Novel Biomarker Identified for Immunoglobulin A Nephropathy

Unraveling the Role of DNASE1L2 Intron Retention in Tuberculosis Progression

New National Digital Series Highlights Evidence-Based Lifestyle Strategies to Achieve Type 2 Diabetes Remission

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.